New Zealand’s world-first combination analgesic	30 October 2009
AFT Pharmaceuticals has released Maxigesic®, a new analgesic tablet which for the first time in NZ combines Paracetamol and the anti-inflammatory Ibuprofen to provide superior pain relief to patients than either agent on its own. AFT will supply Maxigesic® in NZ and Australia and is looking for a partner to sell the drug overseas. The global pain relief market is worth $27 billion a year and group CEO Dr Hartley Atkinson sees massive potential for this product to take a good share of that.
AFT Licensing deal in SE Asia	04 May 2008
AFT Pharmaceuticals has reached agreement with Hoe Pharmaceuticals in Malaysia to license 3 niche pharmaceuticals for the rapidly growing SE Asian market. The first launches will be in Q3 in Malaysia "AFT is very excited to take this next step in our expansion" said group CEO, Dr Hartley Atkinson
AFT growth continues for 31 Mar08 Year	04 May 2008
AFT Pharmaceuticals group sales grew to $22.4 million for the 31st March 2008 year. Sales for this next financial year are targeted to be between $28-30 million announced group CEO, Dr Hartley Atkinson Further sales growth is anticipated in key Australian and NZ markets.
New Key Account Manager in Australia	03 March 2008
AFT Pharmaceuticals is pleased to announce the promotion of Ms Caron Kranenburg to the position of Key Accounts Manager to service our growing business in Australia. "Sales in the next financial year - 1 Apr 08 to 31 Mar09 are targeted to double" said group CEO Dr Hartley ATkinson
AFT tops Australian PBS script growth in % terms	01 November 2007
AFT was listed (Pharma News) as having the top % growth in PBS scripts in the Australian market and #6 in absolute script growth "This is consistent with the rapid growth in sales that we are seeing since the introduction of a dedicated AFT sales force in Australia" said group CEO, Dr Hartley Atkinson
AFT Group Sales Growth continues at +40%	22 September 2007
Growth of 40% per annum continues for AFT Pharmaceuticals in the Australasian market (Australia and NZ) with sales for this year due to break $22 million per annum
AFT Pharmaceuticals Expands Australian Presence	22 September 2007
AFT Pharmaceuticals has increased its Australian presence with its own dedicated sales team of representatives visiting doctors and pharmacists. Strong sales growth (+50% p.a.) continues in the Australian market fuelled by new product introductions and growth of existing products
AFT Pharm NZ to launch 7 new products in Nov/Dec06	03 November 2006
The New Zealand branch of AFT is to launch an unprecedented seven new products in November and December 2006. We believe that this demonstrates our ability to launch new products in the market through our strong sales and distribution network
AFT Pharmaceuticals Grows at 45% per annum	03 November 2006
AFT Pharmaceuticals is continuing to experience strong growth in both the Australian and NZ markets with group turnover in excess of $16 million. Future sales are budgetted in excess of $20 million driven by growth from existing products and new launches
PBS Listing of FerroF Tablets and Cromolux	01 November 2006
AFT Pharmaceuticals Pty Ltd has just successfully launched Ferro-F tablets (iron and folic acid) and Cromolux (sodium cromoglycate eye drops 2%) on the Pharmaceutical Benefit Scheme (PBS) in Australia on 1 August. Stock is available from all major wholesalers
Launch of Ellgy Plus Cracked Heel Cream in NZ	31 October 2006
AFT Pharmaceuticals has now marketed Ellgy cracked Heel cream in the New Zealand market for over a year and has reached a clear 2 position in this competitive market (IMS data) with a combination of rep promotion, print and TV advertising.